Koers AroCell AB (publ) Nasdaq Stockholm
Aandelen
SE0003883990
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 61 mln. 5,58 mln. 5,22 mln. | Omzet 2025 * | 82,4 mln. 7,53 mln. 7,05 mln. | Marktkapitalisatie | 85,69 mln. 7,83 mln. 7,33 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -51 mln. -4,66 mln. -4,36 mln. | Nettowinst (verlies) 2025 * | -32 mln. -2,93 mln. -2,74 mln. | EV/omzet 2024 * | 0,81 x |
Nettoliquiditeiten 2024 * | 36 mln. 3,29 mln. 3,08 mln. | Nettoliquiditeiten 2025 * | 38 mln. 3,47 mln. 3,25 mln. | EV/omzet 2025 * | 0,58 x |
K/w-verhouding 2024 * |
-1,86
x | K/w-verhouding 2025 * |
-3,72
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 44,36% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anders Hultman
CEO | Chief Executive Officer | 50 | 01-12-18 |
Lars Jakobsson
DFI | Director of Finance/CFO | 67 | - |
Gustav Sten
COO | Chief Operating Officer | - | 01-01-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 65 | 01-01-22 | |
Director/Board Member | 63 | 01-05-21 | |
Clas Runnberg
BRD | Director/Board Member | 72 | 01-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |